MC4R(黑素皮質素4受體)途徑 - 開發平台分析:2023年

本報告提供MC4R(黑素皮質素4受體)途徑的相關調查，彙整MC4R途徑的概要與開發平台趨勢，競爭情形，及開發平台藥物簡介等資訊。

目錄

概要

MC4R途徑的標的

• 簡介
• 遺傳學
• MC4R缺損症
• 作用機制
• MC4R抑制劑臨床應用

MC4R途徑開發平台分析，各相

• MC4R途徑開發，概要
• 開發中產品，各開發階段
• MC4R途徑的競爭情形，各相
• 開發中產品，各企業
• 開發中產品，適應症及各相
• MC4R途徑的單劑療法和聯合治療的臨床試驗
• MC4R途徑- 資產，適應症及各相
• MC4R途徑臨床及法規計劃
• 後期階段的簡介的比較概要

MC4R途徑的授權，收購，及合作契約

MC4R途徑開發平台的形勢

• MC4R途徑開發平台藥物簡介

第Ⅲ相

• Setmelanotide (Rhythm Pharmaceuticals, Inc.)
• Lorcaserin (Eisai Inc.)
• PL9643(Palatin Technologies)

第二階段

• Bremelanotide (Palatin Technologies)

第一階段

• PF-07258669(Pfizer)
• TCMCB 07(Endevica Bio)
• LR19021(LG Life Sciences)
• 前臨床
• PL9654(Palatin Technologies)

MC4R途徑的SWOT分析

附錄

The MC4R Pathway pipeline report covers the MC4R Pipeline market opportunity providing Key Competitive Analysis, 6 Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreements, Business Partners as well as Clinical Partner. In addition, our report covers pipeline product analysis by stage of development, competitive landscape by phases, companies, mechanism of action, intervention types. The MC4R Pipeline report adds value in terms of describing clinical-stage products concerning their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers, and challenges.

The MC4R pathway refers to a signalling cascade that is initiated by the binding of certain ligands, such as alpha-melanocyte-stimulating hormone (α-MSH), to the melanocortin 4 receptor (MC4R). This receptor is expressed in various regions of the brain, including the hypothalamus, and plays a critical role in regulating appetite and energy balance. Activation of the MC4R pathway leads to downstream effects that increase energy expenditure and decrease food intake, ultimately resulting in weight loss. This pathway has been the subject of significant research, as mutations in the MC4R gene have been linked to obesity in humans. Targeting the MC4R pathway may represent a promising strategy for the development of new treatments for obesity and related metabolic disorders.

In this report, Mellalta Meets provides an in-depth analysis of MC4R Pipeline covering Phase III , Phase II & Phase I Pipeline Analysis Overview, Pipeline Products by Stage of Development , MC4R Pipeline Competitive Landscape Distinguished by Phase & Route and molecule type, Clinical Pipeline Products by Company, Pipeline Assets by Indication and Phases, MC4R Pipeline Monotherapy & Combinations Clinical Trials, MC4R Pipeline Clinical & Regulatory Timelines, Late-Stage Profiles Comparisons At-a-glance, details of partnerships and business deal values and investments. Currently, there are 8 candidates under evaluation in clinical and preclinical studies. The major key players operating in the market are Pfizer, Eisai. Inc., Rhythm Pharmaceuticals, Inc., Palatin Technologies, and Endevica Bio which have a robust clinical pipeline of MC4R Pathway candidates.

As per analysis, the development pipeline is full of molecules like small molecules, and peptides

Key Highlights of the MC4R Pathway Report:

• There are XX products each in the Phase 3 and Phase 1 stage of development, representing XX% of the total share of the developing MC4R Pathway landscape.

• The pipeline of MC4R pathway is dominated by biotech companies headquartered in United States with US companies holding the 4 positions. They represent XX% of all the MC4R pipeline.

• MC4R Pathway pipeline landscape includes 100% of Monotherapy trials.

• The pipeline of MC4R Pathway is dominated by Phase 3 (3) and Phase 1(3) followed by Phase 2 (1), and pre-clinical (1) assets.

Report Coverage:

• Indication Prioritisation: MC4R Pathway market potential based on Indications.

• Business Transactions & Strategies: Key collaborations and deal values

• MC4R Pathway Pipeline Development: Product Profiles, Clinical Trials & Results

• MC4R Pathway Acquisition Targets

• MC4R Pathway Competitive Intelligence

• Recent & Upcoming events

TABLE OF CONTENTS

OVERVIEW

The MC4R Pathway Target BACKGROUND

• Introduction
• Genetics
• MC4R Deficiency
• Mechanism of Action
• Clinical Application of MC4R Inhibitors

MC4R Pathway PIPELINE ANALYSIS by Phases

• MC4R Pathway Development - Overview
• Pipeline Products by Stage of Development
• MC4R Pathway Competitive Landscape by Phases
• Pipeline Products by Company
• Pipeline Products by Indication and Phases
• MC4R Pathway Monotherapy & Combinations Clinical Trials
• MC4R Pathway- Assets by Indication/Phase
• MC4R Pathway Clinical & Regulatory Timelines
• Late-Stage Profiles Comparisons At-a-glance

MC4R Pathway LICENSING, ACQUISITION, AND COLLABORATION DEALS

• MC4R Pathway Licensing, Acquisition, and Deal values
• MC4R Pathway Licensing by Transaction type and total amount size by Phases

MC4R Pathway Pipeline Landscape

• MC4R Pathway Pipeline Drug Profiles

Phase III

• Setmelanotide (Rhythm Pharmaceuticals, Inc.)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• Lorcaserin (Eisai Inc.)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• PL9643 (Palatin Technologies)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments

Phase II

• Bremelanotide (Palatin Technologies)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments

Phase I

• PF-07258669 (Pfizer)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• TCMCB 07 (Endevica Bio)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• LR19021 (LG Life Sciences)
  • Product Profile & Description
  • Collaborations
  • Other Developments
• Preclinical
• PL9654 (Palatin Technologies)
  • Product Profile & Description
  • Collaborations
  • Other Developments

MC4R Pathway SWOT Analysis

Appendix

• About us